Alternative Splicing Yields Insights Into Cancer Metabolism And Potential New Drug Targets
This article was originally published in Start Up
For the first time, cancer researchers have shown that a variant of the EGF receptor often amplified in glioblastoma upregulates a specific splicing protein that in turn alters cancer metabolism. This increased understanding of the factors controlling so-called “alternative splicing” could offer up a range of new therapeutic approaches in GBM, other cancers, and potentially other diseases.
You may also be interested in...
Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.